Our proprietary StaR® technology and SBDD platform has enabled us to develop small molecules, peptides and antigens for antibody discovery. To date, we have leveraged our technologies and expertise to create a pipeline of drug candidates targeting GPCRs that we believe have potential to become first-in-class or best-in-class medicines in therapeutic areas such as neurology, immunology, gastroenterology and inflammatory diseases.
Our partnered pipeline includes clinical candidates out-licensed to leading pharmaceutical and biotechnology companies, including AbbVie and AstraZeneca, and drug candidates for which we have ongoing single or multi-target discovery and development collaborations, including with AbbVie, Genentech, GSK, Takeda, and Pfizer. Our partners are developing one or more drug candidates that we discovered using our SBDD platform. We believe these strategic partnerships validate our GPCR technologies and SBDD platform capabilities, and also provide a diversified source of revenues in the form of up-front and milestone payments.
Our partnered pipeline also includes drug candidates that we are currently co-developing, or which we plan to co-develop, with collaboration partners under profit and risk-sharing arrangements. We have entered into strategic co-development agreements with Kymab and PeptiDream, for the discovery, development and commercialization of certain novel antibody therapeutics and peptides.
Our emerging pipeline of in-house programs comprise multiple drug candidates that address patient populations across neurology, gastroenterology/immunology, and inflammatory diseases. We plan to further develop these programs through to points of inflection before seeking partnerships with global pharmaceutical and biotech companies.